Background: It is uncertain whether reduction of left ventricular (LV) mass during antihypertensive treatment predicts reduces cardiovascular complications of hypertension. Methods: A total of 172 prospectively identified patients with essential hypertension without complications of hypertension at baseline and follow-up echocardiograms 5.5 Ϯ 3.0 years apart, were followed an additional 4.8 Ϯ 2.9 years. Antihypertensive treatment was determined by primary physicians. 
F
or years, diagnosis and treatment of hypertension have been based on established cut points in a physiologic parameter, blood pressure (BP), rather than on symptoms, biochemical signs, or pathologic findings. Although the strategy of normalizing BP has met with success, this approach to hypertension treatment may reduce coronary disease events less than anticipated. 1 Furthermore, many hypertensive patients suffer no complications, and some may possibly be adversely effected by overly aggressive BP lowering. 2 Recently, investigators have tried to predict the level of risk associated with hypertension by evaluating early and reversible signs of end organ damage, particularly of the heart, the end organ most commonly effected by hypertension. 3 Studies have established echocardiographically determined left ventricular (LV) hypertrophy as an independent risk factor for adverse outcomes in several populations, including patients with hypertension. 4 -7 In hypertensive patients, LV mass has been shown to predict complications and death better than the level of BP. 4 Echocardiographic measurements of LV mass are associated with the severity of BP elevation and other factors associated with cardiovascular disease such as abnormal coronary blood flow reserve, obesity, high sodium intake, and increased blood viscosity. 8 -11 These findings have raised the possibility that LV mass change may provide information about disease progression or its control in response to treatment of hypertension or other conditions. This hypothesis was supported indirectly by electrocardiographic data from Framingham, 12 but not other epidemiologic studies, 13, 14 perhaps due to variability 15 of serial electrocardiographic measurements. In a retrospective analysis of data from 304 patients in a multicenter 4-year trial, the change of echocardiographic LV mass was the variable most strongly associated with morbid events. 16 Two other serial echocardiographic studies 17, 18 reported that patients with regression of LV hypertrophy or persistence of normal LV mass had lower rates of morbid events than those with persistent hypertrophy, but in one study 17 several interim echocardiograms were performed after morbid events.
We have followed a cohort of patients with essential hypertension at Cornell Medical Center in whom the relation of LV mass at enrollment to prognosis has been previously published. 5 The current study reports findings from members of this cohort who remained event-free between serial echocardiograms and were subsequently followed for an average of nearly 6 years.
Methods

Patients
Patients were selected for this study from a cohort of 280 consecutive patients enrolled in hypertension studies at Cornell Medical Center between 1976 and 1981. Informed consent was obtained under protocols approved by the Institutional Review Board. Enrollment procedures, including inclusion and exclusion criteria, have been previously published. 10 Patients were free of secondary hypertension, pre-existing cardiac disease, or severe medical illnesses including diabetes at enrollment into the study.
Patients who participated in the baseline echocardiographic study were periodically contacted and interviewed to assess incident complications of hypertension, antihypertensive treatment, and compliance with medication, diet, and exercise. Interviews were conducted by telephone or in person with patients or immediate family members at intervals beginning Ն1 year after baseline echocardiograms. After the interviews, all patients were invited to Cornell Medical Center for follow-up echocardiograms. Members of the larger group who returned for follow-up echocardiograms or who had echocardiograms performed at Cornell Medical Center at the request of primary physicians are considered in the current analysis.
Eighty patients from the initial cohort of 280 were ineligible for follow-up study due to occurrence of morbid events before follow-up echocardiograms (35 patients), refusal or inability to return for follow-up echocardiograms (25 patients), or loss to clinical follow-up (20 patients). Of the 200 returning patients, 28 (14%) had follow-up echocardiograms that were technically inadequate. All 172 patients in the final cohort had clinical follow-up for at least 1 year after their second echocardiogram.
Complications
Complications after follow-up echocardiograms included death (10 patients), stroke (6 patients), myocardial infarction (6 patients), new onset angina (5 patients), congestive heart failure (1 patients), coronary revascularization by surgery or angioplasty (9 patients), and carotid endarterectomy (1 patient). Criteria used to define complications have been previously reported. 10 Complications were corroborated by patients' physicians, hospital records, and death certificates whenever possible. Investigators were blinded to echocardiogram results during interviews with patients and when classifying possible morbid events. Survival status was ascertained in patients lost to follow-up using the National Death Index, a database of death certificates filed in 50 US states and US territories (National Center for Health Statistics, Hyattsville, MD).
Echocardiograms
M-mode recordings were obtained with commercially available equipment following standard procedures for LV visualization. Echocardiographic tracings were coded and interpreted blindly. Measurements of the interventricular septum, LV internal dimension, and posterior wall at enddiastole were made by Penn and American Society of Echocardiography (ASE) conventions. 19, 20 Penn convention measurements were used to calculate LV mass by an anatomically validated formula. 19, 21 Relative wall thickness was calculated as LV wall thickness/internal radius from ASE measurements.
Follow-up echocardiograms were performed at least 1 year (mean, 5.5 Ϯ 3.0 years) after study enrollment. Investigators interpreted the M-mode echocardiograms of follow-up studies without using new technical features such as B-mode or harmonic imaging, which were not available in echocardiographs used for baseline echocardiograms. When three or more echocardiograms were obtained, only the first two studies were considered. The LV hypertrophy was defined by sex-specific criteria (Ն110 g/m 2 in women and Ն134 g/m 2 in men). 22 Baseline and follow-up BP values were calculated as averages of all measurements by cuff and mercury manometer at the time of echocardiography. In 32 patients, echocardiographic data were obtained from studies ordered by noninvestigator physicians and interim BP was measured at concurrent office visits.
Statistical Analysis
Analyses were performed using BMDP biomedical statistical software (BMDP Statistical Software, Berkeley, CA). 23 Univariate comparisons between groups used twotailed t tests for continuous variables and Fisher's exact tests for dichotomous variables. Correlation coefficients were used to evaluate the relationship between changes in LV mass and BP. Life table analyses compared life-years free of cardiovascular events between groups. Confidence intervals (CIs) of 95% were used where appropriate. Mul-tivariate analyses used forward stepwise multiple logistic regression with P to enter of .05 and to exclude of .10. P Ͻ .05 was considered statistically significant.
Results
Baseline Characteristics
The 172 subjects (109 men and 63 women) were followed for a total of 11.3 Ϯ 2.5 years of which 5.8 Ϯ 2.9 years was after follow-up echocardiograms (Table 1) . At initial enrollment, patients were mildly or moderately hypertensive. Patients whose LV mass was the same or decreased from baseline to follow-up had slightly higher initial BP (systolic: 154 mm Hg v 150 mm Hg, P ϭ .14; diastolic: 97 mm Hg v 94 mm Hg; P ϭ .04) and greater BP reduction between baseline and follow-up than patients in whom LV mass increased (Ϫ7.7 mm Hg v Ϫ0.9 mm Hg/Ϫ5.3 mm Hg v Ϫ1.5 mm Hg diastolic, P ϭ .01/.05). As a result, BP at follow-up echocardiography was similar in both groups. A majority of patients experienced decreases in systolic (56%) and diastolic (57%) BP during follow-up.
Other baseline characteristics were unrelated to changes in LV mass during follow-up (Table 1) . Race, duration of hypertension, tobacco use, and baseline levels of serum cholesterol and creatinine were similar in groups with increased or decreased LV mass, as was body size at baseline and during follow-up. Relations between changes in LV mass and BP were poor (r ϭ 0.07 for systolic and r ϭ 0.08 for diastolic BP). All patients received some form of antihypertensive treatment and 83% of patients used medication during all or most of the follow-up period.
Fewer than one-third of subjects used the same medication throughout the follow-up period, more than half used more than one medication, and nearly half of patients admitted missing medication "some of the time" or "frequently."
Incidence of LV Hypertrophy
At baseline echocardiography 38 patients (22%) had LV hypertrophy and 134 patients had normal LV mass. At follow-up, 16 of 38 patients (42%) with hypertrophy had reduction of LV mass to normal levels and 20 of 134 (15%) patients with initially normal LV mass developed hypertrophy. The absolute level of LV mass decreased in 88 patients (51%), stayed the same in 3 patients (2%), and increased in 81 patients (47%) during follow-up.
Events
During follow-up after the interim echocardiogram, 34 cardiovascular events (3.2 per 100 patient-years) occurred in 24 patients or 14% of the population (Table 2) . Events occurred after the follow-up echocardiogram in fewer patients in whom LV mass had decreased or stayed the same than in patients whose LV mass increased (8.8% [95% CI 3.9%-13.7%] v 19.8% [95% CI 12.6%-27.0%]; P ϭ .04) (Fig. 1) . This finding was confirmed in life table analyses showing that patients with decreased as compared to increased LV mass had significantly greater event-free survival (P ϭ .04) (Fig. 2) . Events occurred in 11 of 114 (9.6%) of patients free of hypertrophy both at baseline and follow-up and in 1 of 16 (6.3%) of patients with regression of baseline hypertrophy to normal mass (Fig. 3) . More patients suffered events among those with normal baseline mass who developed hypertrophy during follow-up (6 of 20, 30%) and those with hypertrophy throughout the study (6 of 22 patients, 27%; P Ͻ .001 by analysis of variance) (Fig. 3) . The event rate was strikingly higher in patients with hypertrophy than normal mass at follow-up (9.2% v 28.6% or 1.6%/year v 3.8%/year; P ϭ .004). There was no relation between the interval between echocardiograms and prognosis. Nine deaths, 4 cardiovascular and 5 noncardiovascular, occurred in 7 men and 2 women during follow-up. Deaths occurred in 6 of 130 patients (5%) with normal LV mass and in 3 of 42 patients (7%) with LV hypertrophy at 
FIG. 1.
The proportion of patients suffering cardiovascular events after the follow-up echocardiograms was significantly (P Ͻ .001) lower in patients whose left ventricular (LV) mass decreased or remained unchanged between echocardiograms than in those in whom it decreased.
FIG. 2.
Event-free survival (vertical axis) was significantly lower (P Ͻ .04) in patients whose LV mass increased (dashed line) than in those in whom it decreased or remained unchanged (solid line) between echocardiograms. Abbreviation as in Fig. 1 .
follow-up. Although three of four cardiovascular deaths occurred in patients with increased mass, there were no significant differences in mortality between groups with and without LV hypertrophy or by changes in LV mass. Event rates did not correlate with changes in BP. Patients with reduced systolic BP at their second evaluations had subsequent events similar to patients with increased follow-up systolic BP (16% [95% CI 9%-23%] v 11% [95% CI 5%-17%]; P ϭ .35). In further analyses, no level of BP lowering predicted reduction in morbid events. Neither the type, number, nor the consistency of use of antihypertensive drugs was statistically related to morbid events. Adverse outcomes correlated more closely to indices of LV mass, especially LV mass index at follow-up, than to BP levels (Table 3) . In multivariate models, the level of LV mass at follow-up was the strongest and most consistent predictor of outcome. Total cholesterol and age were significant predictors in some multivariate models. Summary statistics of multivariate analyses are shown in Table 4 .
Discussion
Left ventricular hypertrophy is a common manifestation of elevated BP that can be modified with therapy. Although LV hypertrophy is an adaptive response that reduces LV wall stress in the face of elevated arterial BP, 24 it is also an ominous prognostic sign that integrates hemodynamic and nonhemodynamic factors associated with cardiovascular morbidity. 4 -11,25 Initial prognostic data support but do not prove the attractive hypothesis that LV mass reduction predicts an improved prognosis and is thus a desirable outcome of antihypertensive therapy. 12,16 -18 The current study supports the relevance to prognosis of serial LV mass measurements during treatment in a cohort of prospectively identified patients with uncomplicated mild-to-moderate essential hypertension. We found that patients with reduced LV mass, measured after an average follow-up of 5.5 years, were only about 40% as likely to suffer morbid events during the next 5.8 years as patients with increased LV mass at the intermediate echocardiogram. Of note, this reduction in morbidity occurred in a group who were initially anticipated to be at greater risk for hypertensive complications due to higher LV mass and clinic BP at baseline. The study also shows that development or maintenance of LV hypertrophy during follow-up is an ominous sign associated with a cardiovascular complication rate of 5% per year.
Patients with reduced BP at follow-up experienced as many complications as subjects with increased follow-up BP. This finding is not surprising in view of previous studies that have required observation of 10,000 patientyears or more to demonstrate prevention of coronary disease events by pressure lowering in mild-to-moderate hypertension. In contrast, in the current study, LV mass reduction was shown to be a useful risk stratification tool in less than 1000 patient-years of follow-up. By reducing observation time in patient-years by an order of magnitude, measurement of LV mass may be useful for providing initial estimates of prognostic benefits of future treatments of hypertension. 26 Our results have potential implications for clinical management of hypertension. This study and previous ones support the concept that LV mass measurement can help identify patients especially likely to benefit from antihypertensive therapy. 12,16 -18 The study also shows that follow-up echocardiograms after several years of treatment help assess the subsequent level of risk in treated hypertensive patients. The LV mass measurement may be par- Tables 1 and 2 . Statistical significance: * P Ͻ .05; † P Ͻ .01; ‡ P Ͻ .001.
FIG. 3.
The percentage of patients suffering morbid events (vertical axis) was lower (P Ͻ .004) in patients with normal follow-up LV mass (left) than with elevated follow-up LV mass (right). LVH ϭ LV hypertrophy; other abbreviation as in Figs. 1 and 2 .
ticularly useful in groups of patients for whom office BP levels may misrepresent the severity of BP elevation or fluctuate widely. For example, in young women, a group with a high prevalence of white coat hypertension, 27 normal LV mass might support a decision to withhold pharmacologic treatment of hypertension. In contrast, in groups at high risk for hypertensive complications, such as African Americans or diabetics, the finding of increased LV mass might justify pharmacologic therapy for borderline or even high-normal BP. Persistence of LV hypertrophy in hypertensive patients with adequate BP control during office visits should raise concerns about the appropriate target level for BP lowering, compliance with medication, or underlying coronary or other forms of heart disease.
Hypertensive LV hypertrophy is reversed in many, but not all, patients by antihypertensive therapy. Available data suggest that different classes of antihypertensive agents may have different effects on LV size and mass despite similar BP lowering. 28, 29 Agents that interrupt the renin-angiotensin system may be most effective at reducing LV mass, whereas direct-acting vasodilators are least effective.
Concerns about the cost of routine echocardiography for hypertensive patients have been raised and addressed. 30 Focused LV echocardiograms provide sonographic information relevant to hypertensive patients while foregoing other time consuming and costly features of a complete echocardiographic examination. Results of the present and previous 16 -18 studies suggest that restratification of risk by echocardiography at intervals of several years may provide clinically useful information but do not provide any support for frequent use of echocardiography to help fine-tune antihypertensive therapy.
Several limitations of the study merit consideration. First, our inclusion criteria probably excluded patients with the most and least severe disease, and may not be representative of patients with more or less complicated hypertension. Patients were prospectively selected to be free of overt cardiovascular disease or confounding factors at both baseline and at echocardiographic follow-up. Therefore, our cohort was free of patients who develop complications within a short period after the diagnosis of hypertension and our findings may not apply equally to recently diagnosed patients. Conversely, our patients may be at higher risk for complications than some other populations, as many patients in the study had suboptimal compliance with prescribed medication or nonpharmacologic regimens for at least part of the follow-up period. Furthermore, our patients received diverse and in many instances, multiple antihypertensive regimens during follow-up, limiting the ability either to analyze the impact of different therapies or to exclude its relevance to the findings.
Second, the optimal timing of follow-up echocardiography was not assessed in the study. Although we encouraged cohort members to participate in follow-up echocardiograms periodically, many of our patients did not reside near the medical center during the follow-up period and were able to return for only one follow-up echocardiogram, which was performed at their convenience. We found no relationship between the time between echocardiograms and prognosis.
Third, technically adequate echocardiograms were not obtainable at the interim examination in 14% of otherwise eligible patients. Subjects with suboptimal echocardiograms were older than other subjects and, therefore, at greater risk of hypertensive complications. Improvements in echocardiographic equipment and technique have substantially reduced this problem. 31 Fourth, our a priori definition of events included new onset angina, angioplasty, and bypass surgery-outcomes based on clinical decision making and subjectivity. Our study was not powered to assess only hard outcomes. A larger study would be required to evaluate whether our findings extended to end points such as stroke, myocardial infarction, or death.
Finally, all studies that assess the relation between changes in a parameter over time and outcome are subject to errors due to the statistical phenomena of regression to the mean. 32 Regression to the mean is particularly problematic in analyses that use cut points and may affect our analyses with respect to LV hypertrophy status (based on cut points of Ն134 g/m 2 in men and Ն110 g/m 2 in women) at baseline and follow-up. It can be argued that some patients with LV hypertrophy at baseline who became normal at follow-up may have had an overestimation of their initial LV mass making it appear that their risk was diminished by LV mass reduction when, in fact, their initial risk was not elevated. Fortunately, this statistical problem is ameliorated by our analyses that divide patients NS ϭ not significant; other abbreviations as in Tables 1 and 2 . P Ͼ .15.
into two nearly equal groups based only on whether LV mass increased or decreased between baseline and followup. Because the likelihood of overestimating initial LV mass is greatest in those with the highest baseline values, patients incorrectly characterized into the decreased mass group based on statistical fluctuation rather than change in underlying LV mass are actually likely to have above average true LV mass making this a conservative approach to analysis. Furthermore, the substantially higher initial level of LV mass measured in the decreased mass patients makes it extremely unlikely that these patients were actually at lower risk than the increased mass patients at baseline whose LV mass increased between serial echocardiograms.
In summary, this report shows that serial measurement of LV mass during treatment of essential hypertension provides information about the prognosis of patients receiving conventional antihypertensive therapy. On the basis of our observations and other available data, 12,16 -18 LV mass reduction appears to be a desirable outcome of hypertension therapy and the development or persistence of LV hypertrophy during treatment to be a particularly ominous sign. Additional research in clinical trials with specified treatment and careful assessment of treatment compliance and BP effects is needed to establish LV hypertrophy regression as an indication for therapy and a useful surrogate end point for prognosis in future trials of antihypertensive therapy. 31, 33, 34 
